

EVEXIAS  
Email Campaign #1

**Provider-facing Email Copy**

**Subject:** Give Patients the Gift of Health Freedom

**Protect Your Patient's Right To Thrive  
Donate to Safeguard Peptide Therapy Now**

In October, the FDA moved 17 peptides onto the Category 2 Bulk Substances List.

This reclassification prevents compounding pharmacies from formulating potentially life-changing peptide therapies for patients with few other alternatives. It also limits the care options providers can offer patients and denies patients the right to choose the care path that suits them best.

You can help protect peptides and patient autonomy! Each donation to the Peptide Legal Fund helps urge the FDA to reevaluate this decision by funding research and advocacy efforts.

**PRESERVE MEDICAL FREEDOMS  
[DONATE BUTTON]**

---

**Patient-facing Email Copy**

**Subject:** Join Us in Protecting Your Health Freedom

**Protect Your Right To Thrive  
Donate to Save Peptides Today!**

In October, the FDA moved 17 peptides onto the Category 2 Bulk Substances List, preventing peptide compounding pharmacies from creating potentially life-changing drugs, and barring patients from exercising their right to choose the medical care that suits them best.

The peptides recently reclassified are long-standing formulations, highly sought after for their potential medical benefits. Research shows that peptide therapy may help with weight loss, anti-aging, chronic conditions like Irritable Bowel Syndrome, and even cancer.

You can help protect access to peptide therapy and preserve your autonomy as a patient! Each donation to the Peptide Legal Fund helps urge the FDA to reevaluate this decision by funding research and advocacy efforts.

**PRESERVE YOUR MEDICAL FREEDOMS**  
**[DONATE BUTTON]**